Dopaminergic RestauratIon by IntraVEntriculaire Administration

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 18, 2020

Primary Completion Date

May 6, 2024

Study Completion Date

May 6, 2024

Conditions
Parkinson Disease
Interventions
DRUG

A-dopamine

"During the phase 1 (titration), it is planned to increase dopamine by maximum 0.25 mg per hour over the daytime period, which corresponds to a maximum increase of 4.5 mg per day (based on the 18 hours of the daytime period, since nocturnal needs are much less important).~Then, depending on tolerance and efficacy, conservative titration will be continued for a target dose of 30-87 mg per day.~During the phase 2 (efficacy), the treatment will be maintained at the minimum effective dose, planned between 30 and 87 mg per day, for 30 days."

DRUG

optimized oral treatment

The patient will received his usual dopaminergic treatment.

Trial Locations (1)

59037

Hopital Roger Salengro, CHU Lille, Lille

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

InBrain Pharma

UNKNOWN

lead

University Hospital, Lille

OTHER

NCT04332276 - Dopaminergic RestauratIon by IntraVEntriculaire Administration | Biotech Hunter | Biotech Hunter